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The ageing of the population in western countries, the 
continuous increase of the prevalence of chronic diseases, 
the frequent coexistence of several morbid conditions 
(comorbidity) requires health professionals and 
Institutions to face difficult challenges, including 
increasing costs, need for more effective and sustainable 
therapies, and organizational issues. 
The European Innovation Partnership on Active and 
Healthy Ageing aims at enabling European citizens to lead 
healthy, active and independent lives while ageing.  
We herein discuss some key concepts bearing a special 
significance in the light of the Partnership aims, and 
present research and educational projects active in our 
local environment. Among these, the multicentre project 
TOSCA (Trattamento Ormonale nello Scompenso 
CArdiaco) that, although primarily focused on the 
understanding of the interactions between hormones and 
chronic heart failure (CHF), is also aimed at developing 
more effective models of clinical care. We provide the 
scientific background and current stage of the project. In 
the context of a growing complexity of the patients’ 
clinical management, the polipharmacy is a new arising 
challenge for clinicians, bearing direct economic, 
organizational and clinical implications. A better 
understanding, characterization and management of this 
issue represent an additional target of the TOSCA 
network.    
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THE EUROPEAN INNOVATION PARTNERSHIP ON 
ACTIVE AND HEALTHY AGEING 
 
The European Innovation Partnership on Active and 
Healthy Ageing will pursue a triple result for Europe: 
enabling European citizens to lead healthy, active and 
independent lives while ageing; improving the 
sustainability and efficiency of social and health care 
systems; boosting and improving the competitiveness of 
the markets for innovative products and services 
responding to the ageing challenge.  
This will be realised in the three areas of prevention and 
health promotion, care and cure, and active and 
independent living of elderly people. The overarching 
target of this partnership will be to increase the average 
healthy lifespan by two years by 2020. 
The Partnership aims to achieve this by bringing together 
all actors in the innovation cycle, from research to 
adoption, along with those engaged in standardisation and 
regulation. The Partnership aims at improving the 
framework conditions for uptake of innovation, improve 
coordination between funding for social and medical 
innovation at European, national and regional level in 
Europe. 
This altogether will foster innovation in products, 
processes and services and, ultimately, will produce 
benefits for the final users: the older people and care 
providers [1].  
Chronic Heart Failure (CHF) is among the most 
frequent and complex disease in the elderly, leading to 
significant functional and social impairment as well as 
high costs.  
In many European countries, > 2% (2.4% in Italy) of the 
total healthcare budget is related to HF management and 
up to 70% (80% in Italy) of this cost are related to 
hospitalizations. In Italy, the pharmaceutical cost 
represents about 15% of the total health care budget 
related to HF (150 million Euro/year; 1,3% of the total 
pharmaceutical cost) [2-3].  
Moreover, the recent “device” therapy for HF is further 
increasing the economic burden for HF management. It 
has been estimated that an ICD implantation strategy 
based on current guidelines would increase the rate of 
implants in Italy by 68% in a 5-year time-frame, 
impacting heavily on public health system resources. 
These data suggest the urgent need for effective and better 
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risk stratification to maximize the benefit of ICD therapy 
and reduce costs in primary prevention [4]. 
 
EPIDEMIOLOGY OF CHRONIC HEART FAILURE  
 
Chronic Heart Failure is a growing public health problem 
impacting heavily on patient survival, quality of life and 
healthcare costs. The incidence and prevalence (2-3 of the 
general population) are clearly increasing in industrialized 
countries [5-6]. CHF is characterized by (a) shortness of 
breath at rest or during exertion, and fatigue; (b) signs of 
fluid retention such as pulmonary congestion or ankle 
swelling; (c) and an objective evidence of an abnormality 
of the structure or function of the heart at rest [2].  
CHF is a notable exception in the field of cardiovascular 
disease (CVD). Despite the major improvements obtained 
in the management of virtually all CVD, CHF still 
represent a major social and health problem, representing 
the second most common cause of hospital admission in 
the world [7] (200.000/year in Italy; 2% of total hospital 
admissions [8]). CHF is also burdened by unacceptable 
high hospital readmission rate (approximately 25%) [9], 
with relevant consequences in terms of health care-cost, 
patients quality of life and mortality [10-12]. 
In the ESC-HF Pilot survey, 5118 HF patients 
(1892 acute HF; 3226 CHF) were enrolled by 136 
participating centers in 12 European countries. In the 
population of acute HF, the survey estimated that the total 
in-hospital mortality was 3,8% and the length of hospital 
admission was 8 days [13]. These findings are not 
congruent to those reported by the registry of the Italian 
Association of Hospital Cardiologists, ANMCO. In this 
survey 5643 patients (1868 acute HF; 3775 CHF) were 
enrolled by 64 participating centers, and estimated a 
higher in-hospital mortality rate (6,4%) and length of 
hospital stay (9,78 days) [3,14]. However in both 
registries (a) in-hospital patients were generally older than 
ambulatory patients and more often female; 2) co-
morbidities were more frequent in patients admitted for 
acute HF, whereas the rate of implanted devices was more 
common in patients with chronic HF [13]. 
 
HEART FAILURE IN ELDERLY 
 
The prevalence of HF rises with age (from 2–3% to 10–
20% at the age of 70–80 years), so that about half of the 
people with HF are 75 years old [2]. The high prevalence 
of preexisting structural and functional abnormalities of 
the heart and that of co-morbidities may explain the worse 
prognosis of HF in older than in young patients [15]  
However, a recent population-based study (2001 
residents in Central Italy; age 65-84; prevalence of overt 
HF 6.7%) estimated a high prevalence of preclinical HF in 
elderly (59,1%) who do not have risk factors treated at 
target, suggesting the need of better HF prevention and 
detection in the older population [16].  
Several surveys, including the Euro Heart Failure 
Survey I (EHFS I) suggest that outcome is particularly 
poor in elderly patients and that evidence-based therapies 
are less frequently used and underdosage of recommended 
medications is constantly found in the elderly [17].  
In a national HF audit, age below 75 years was one of the 
strongest predictors of prescribing evidence-based 
treatments on discharge, and it is likely that the lower 
rates of prescribing may contribute to the pooper 
prognosis in elderly HF subjects. 
The overall management of CHF in elderly 
implies a personalized balance between several factors in 
order to prescribe the best therapy for the individual 
patient and to review it at regular timepoints (see 
paragraphs below). 
 
COMORBIDITIES AND GUIDELINES ADHERENCE 
IN ELDERLY 
 
Elderly patients with HF have a high burden of 
comorbidities and functional and cognitive impairments. 
Some of these conditions are associated with a greater 
mortality risk. In a recent study, Authors examined the 
prevalence of comorbidities and 4 measures of functional 
and cognitive impairments in 558 participants from the 
Cardiovascular Health Study who developed incident HF 
between 1990 and 2002 (mean age of participants 79.2 ± 
6.3 years, 52% men). Participants were followed 
prospectively for more than ten years to determine their 
mortality risk. Comorbidities were: hypertension, 
coronary heart disease, peripheral arterial disease, atrial 
fibrillation, obstructive airway disease, diabetes mellitus, 
chronic kidney disease, cerebrovascular disease, 
depression.  
Sixty percent of participants had ≥3 comorbidities, and 
only 2.5% had none. Twenty-two percent and 44% of 
participants had ≥1 activity of daily living (ADL) and ≥1 
instrumental activity of daily living (IADL) impaired, 
respectively. Seventeen percent of participants had 
cognitive impairment (modified mini-mental state exam 
score <80, scores range 0-100). During follow up, 504 
participants died, with 1-, 5-, and 10-year mortality rates 
of 19%, 56%, and 83%, respectively. In a multivariable-
adjusted model, the following were significantly 
associated with greater total mortality risk: diabetes 
mellitus (hazard ratio [HR]: 1.64), chronic kidney disease 
(HR: 1.32 for moderate disease; HR: 3.00 for severe), 
cerebrovascular disease (HR: 1.53), depression (HR: 
1.44), functional impairment (HR: 1.30 1 IADL impaired; 
HR: 1.49 for ≥2 IADL impaired), and cognitive 
impairment (HR: 1.33). Other comorbidities 
(hypertension, coronary heart disease, peripheral arterial 
disease, atrial fibrillation, and obstructive airway disease) 
and measures of functional impairments (ADLs and 15-ft 
walk time) were not associated with mortality [18].  
Apart from comorbidity, elderly patients present unique 
clinical attention with regard to frequently unrecognized 
conditions.  For example, elderly hospitalized patients 
suffer disproportionately from constipation. In a 
retrospective analysis of elderly patients with CHF 
exacerbations, failure to use constipation prophylaxis is 
associated with a significantly longer length of stay  [18]. 
These data suggest that routine use of bowel prophylaxis, 
a very easy and cheap action, may reduce the duration of 
hospitalization in elderly CHF patients with preexisting 
constipation [19]. The fact that elderly patients with heart 
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failure are likely to be vulnerable or frail, demonstrate the 
importance of a multidisciplinary approach to care. 
 The therapeutic approaches for HF patients have 
remained practically unchanged during the last two 
decades. Following several successful trials in HF, 
effective treatments in the recommendations of current 
guidelines have been included. However, several studies 
showed that guidelines are adopted slowly or 
inconsistently, often failing to lead to further 
improvements of patient care quality (Tab. 1).  
 
Tab. 1. Registries evaluating therapy adherence in CHF. 
 
Underuse and underdosage of medications recommended 
for heart failure have been specifically demonstrated in 
the elderly population by the EHFS II [20]. This study 
showed that a large proportion of patients are not 
discharged on guidance-indicated treatments.  
The possible reasons for this include a poorer awareness 
of the use of heart failure treatments in the elderly. Other 
reasons include the wider prevalence of comorbidities and 
frailty in the elderly, and increased side effects from 
medications, which can significantly limit the use of heart 






Fig. 1. Factors related to HF drug prescription in elderly 
 
Recent surveys show that the overall guideline adherence 
is slowly improving over the last decade as results of more 
effective medical education and physician awareness. 
With respect to device implantation, the gap between 
guidelines and practice seems to be greater, probably due 
to different local medical practice but also to differences 
in healthcare systems [20]. 
Thus, one of the most-cost effective ways to reduce the 
overall burden of HF is the improvement in current 
guideline adherence. 
In this regard, real-world registries based in specific 
geographical areas are crucial to build a reliable portrait of 
prescribing performance, device implantation rate, etc. 
In the Table 1, the most valuable experiences of 
guideline’s adherence assessment are reported. 
 Similarly to the mentioned Registy-based studies, the 
TOSCA project (see below) represent a further 
opportunity to describe the HF drug prescription pattern in 
different clinical settings (internal medicine, cardiology, 
out/inpatients) and to identify major determinants of 
under- or mis-prescriptions. The yearly comparison of the 
performances of different Italian HF units may represent a 
powerful tool for the improvement of the overall medical 
management in HF. Moreover, it will help to identify the 










Polypharmacy is one of the most relevant health-related 
issues in elderly population. Drug treatment may influence 
both positively and negatively elderly health status.  
Polypharmacy increases the risk of inappropriate 
prescribing, drug–drug and drug–disease interactions, and 
hence the risk of adverse health events including falls, 
functional impairment, and hospitalization [20].   
Nowadays, different sets of indicators have been 
developed in order to provide a measure of prescribing 
performance and, hence, to assess the quality of care in 
older people. However, this may not be sufficient for frail 
elderly who have several problems related to the 
functional status, mobility, cognitive status and living 
condition.  In these patients, the most appropriate 
approach to re-evaluate the drug-therapy should combine 
evidence-based data with information gathered from a 
multidimensional geriatric assessment.  
 Polypharmacy is associated to a higher hospitalization 
rate, lower quality of life, increase in health costs, 
reduction in the patient’s compliance and a lower overall 
survival. 
 The network described below is also engaged in the 
study of this phenomenon. To this aim, we are collecting 
retrospective and prospective data in order to characterize 
the pharmacotherapy in patients cared in different centres 
and settings: inpatients, ambulatory patients; general care 
vs. Registry-based care.  
 The systematic review of the drug prescription 
patterns and comorbidities in our HF patients may reveal 
common therapeutic practise that are not evidence-based, 
not associated to any measurable clinical benefit or even   
harmful for the patients. This might have immediate 
implications for the real-world practise by: 
 
 
a. reduce inappropriate drug prescription 
b. arise the awareness for potential drug-drug 
interactions 
c. increase the patients engagement in the 
therapeutic process 




This first large-scale review process may promote the 
development of special ambulatory structures aimed at 
critically review the prescribed treatment in patients on 
polypharmacy. 
 
THE TOSCA PROJECT 
 
The quest for novel biological systems involved in HF 
pathogenesis is very active.  In this regard, there is 
increasing evidence that anabolic hormones are down-
regulated in CHF patients, thus pointing to a Multiple 
Hormonal Deficiency Syndrome (MHDS) that represents 
a reverse model characterized by down- rather than up-
regulation of biologically active molecules. The list 
includes growth hormone (GH) and its tissue effector 
insulin-like growth factor-1 (IGF-1), androgens, thyroid 
hormones and insulin axis [30]. Importantly, deficiency of 
anabolic axes in CHF is consistently associated with 
impaired functional capacity and poor outcome [31]. In 
particular, with regard to GH and testosterone, 
encouraging studies addressing safety and efficacy of 
hormonal therapies have been carried out [32,33]. 
Given this background, the TOSCA (Trattamento 
Ormonale nello Scompenso CArdiaco) Registry is aimed 
at identify specific patterns of hormonal remodeling in 
CHF, their correlation with anthropometric and clinical 
variables, and prognostic implications [34]. 
The TOSCA Registry is a prospective 
multicenter observational study designed to evaluate the 
prevalence of MHDS in CHF patients and its impact on 
the outcomes of patients affected by CHF. The TOSCA 
Registry was set up in April 2013 and so far includes 21 
centers from all over Italy (Fig. 3). The study is 
coordinated by the Department of Traslational Medical 
Sciences - “Federico II” University of Naples (Italy). The 
study will last for 5 years with an average patients’ 
follow-up of 3 years. The main outcome measure for this 
study will be: 
 
- primary end-point: all cause mortality; 
- secondary end-point: cardiovascular mortality; 
hospitalization for decompensated HF. 
 
Patients will be enrolled with the following inclusion 
criteria:  
 
1) patients of both sexes affected by CHF, 
diagnosed following current ESC guidelines;  
2) left ventricular ejection fraction less than 40%  
3) written informed consent.  
Exclusion criteria will be:  
1) end-stage renal disease requiring dialysis 
treatment  
2) liver cirrhosis class C (Child Pugh)  
3) active malignancy  
4) active autoimmune disease  
5) acute coronary syndrome in the previous 6 
months. 
 
All patients will be on top of optimal therapy according to 
current guidelines.  
This ambitious program is made possible with the effort of 
a well-matched national network involving more than 20 










Fig. 2. The TOSCA network 
 
Patients’ recruitment has started at the coordinating center 
on April 2013 and has been gradually extended to the 
other participating centres. The figure below depicts the 
trend of the CHF patients’ enrolment to date, and the 
estimated total enrolment at the end of 2015. 
 
 
Fig. 3. Enrollment rate in the TOSCA Registry 
 
Patients enrolled in the TOSCA Registry will undergo a 
clinical, instrumental, as well as blood work including five 
sample of serum stored at -80°C at baseline, and 
subsequently every year. One sample out of five will be 
employed for centralized measurement of hormones 
targeted by the study (testosterone, IGF-1, DHEA-S, 
insulin) while the others will be stored for subsequent 
analysis to explore new potential features of the CHF 
pathophysiology. 
We think the TOSCA Project will significantly contribute 
to the aims of the European Innovation Partnership on 
Active and Healthy Ageing by providing new tools 
prognostic stratification in adult and elderly HF patients. 
Moreover, the TOSCA project can be considered a 
multifunctional platform with education opportunities for 
HF specialists, cardiologists, internists. During its early 
years, several TOSCA-sponsored events have been held in 
different centres belonging to the TOSCA network. These 
meeting will serve many purposes: 
 
1. To periodically update on the ongoing scientific 
projects 
2. To encourage the young professionals 
engagement in scientific activities 
3. To review and discuss pertinent international 
guidelines 
4. To share HF care models from different setting 
and environment (hospital/university/outpatients) 
 
To further strengthen the educational mission of the 
TOSCA project, a stable partnership with the “The 
Mediterranean School of Cardiovascular Sciences” has 
been established. The School, founded in Amalfi in 
October 2011, represents a crossroads of free knowledge 
and cultures in the heart of the Mediterranean and is at its 
second edition (October 2014). The dedicated website is 
http://www.med-school.info/2015/it/ [35]. In this portal, 
there is a special section for the TOSCA projects, 
including upcoming events, monthly newsletter, slide sets, 
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